Blockade of GPER-dependent EGFR transactivation in breast cancer cells is effective using a Gβγ-sequestrant peptide (131), and further study is needed to evaluate whether Gβγ-inhibitors are effective in mouse models of metabolic disorder and cancer. This evidence concerns the gene EGFR and metabolic disease.